• PTX3 Protects Against Steroid-Induced ONFH via TLR4/NF-κB-FG

  2026-07-02

  This study uncovers a protective mechanism by which pentraxin 3 (PTX3) counters glucocorticoid-induced osteonecrosis of the femoral head (ONFH) through modulation of the TLR4/NF-κB/FGF21 signaling pathway. These findings highlight PTX3 as a potential therapeutic target and offer mechanistic insights for future research into bone preservation strategies under steroid challenge.

• Paroxetine Mesylate: SSRI, CYP2D6 Inhibitor, and Oncology Ut

  2026-07-02

  Paroxetine Mesylate is a selective serotonin reuptake inhibitor (SSRI) with confirmed multi-kinase and cytochrome P450 inhibition. Its characterized in vitro and in vivo activities span neuropsychiatric, oncology, and translational research, supporting robust experimental workflows.

• CTOP (SKU B5135): Reliable μ-Opioid Receptor Antagonist Solu

  2026-07-01

  This article addresses core experimental challenges in opioid receptor research, demonstrating how CTOP (SKU B5135) from APExBIO enables reproducible, data-driven answers for μ-opioid receptor antagonist studies. Integrating scenario-based Q&A and recent literature, it guides researchers towards robust protocol design and interpretation.

• Trichostatin A (TSA) in Organoid Epigenetics: Beyond Oncolog

  2026-07-01

  Explore how Trichostatin A (TSA) revolutionizes epigenetic research in organoid systems and cancer, with a focus on stem cell differentiation and assay optimization. This article reveals new insights for researchers seeking advanced applications of TSA.

• SCH772984 HCl: Advanced Insights into ERK1/2 Inhibition and

  2026-06-30

  Discover how SCH772984 HCl, a potent ERK1/2 inhibitor, reveals novel connections between MAPK pathway inhibition and transcriptional regulation, with direct implications for cancer and metabolic research. This in-depth analysis uniquely integrates mechanistic, assay, and translational perspectives.

• CTOP in Advanced μ-Opioid Receptor Signaling Inhibition Rese

  2026-06-30

  Explore how CTOP, a potent μ-opioid receptor antagonist, enables unprecedented precision in dissecting opioid signaling pathways. This article reveals unique mechanistic insights and practical assay guidance not covered elsewhere.

• Chloramphenicol in Plasmid Surveillance: Modern Assay Design

  2026-06-29

  Explore chloramphenicol's multifaceted role as an antimicrobial agent and bacterial protein synthesis inhibitor in advanced plasmid surveillance assays. This article uniquely connects molecular protocols with real-world resistance transmission, offering guidance for robust research workflows.

• Cholesterol Impairs Lipid Nanoparticle Trafficking in Cells

  2026-06-29

  This study reveals that elevated cholesterol within lipid nanoparticles (LNPs) hinders their intracellular trafficking, leading to impaired nucleic acid delivery. By dissecting the lipid composition using advanced imaging and a DNA tracking platform, the authors clarify how cholesterol disrupts endosomal escape—a critical step for LNP-based gene delivery.

• 3-Bromopyruvate and Cetuximab Synergy Triggers Ferroptosis i

  2026-06-28

  This study demonstrates that co-treatment with 3-bromopyruvate (3-BP) and cetuximab overcomes resistance in colorectal cancer (CRC) cells by inducing autophagy-dependent ferroptosis and apoptosis. Mechanistic insights reveal that restoration of FOXO3a signaling underpins this effect, suggesting actionable targets for overcoming drug resistance in KRAS/BRAF-mutant and acquired-resistant CRC models.

• PDK4-IN-1 Hydrochloride: Precision PDK4 Inhibition in Metabo

  2026-06-27

  PDK4-IN-1 hydrochloride delivers nanomolar selectivity for pyruvate dehydrogenase kinase 4, enabling rigorous control of mitochondrial energy metabolism in cell-based and animal models. This guide translates advanced findings into practical workflows, troubleshooting, and comparative insights for metabolic, oncological, and cardiac hypertrophy research.

• Flumequine: DNA Topoisomerase II Inhibitor in Cancer Researc

  2026-06-26

  Flumequine enables precise and reproducible DNA topoisomerase II inhibition, transforming DNA replication and drug response assays in oncology and antibiotic resistance research. Its robust solubility and validated inhibition parameters equip researchers for high-fidelity experimental workflows and streamlined troubleshooting.

• Applied nor-NOHA Acetate: Precision Arginase Inhibition Work

  2026-06-26

  nor-NOHA acetate empowers cancer and vascular researchers to precisely probe arginase-linked pathways, modulate nitric oxide production, and dissect complex cell fate decisions. This guide details advanced protocols, troubleshooting strategies, and translational insights for maximizing reproducibility and scientific impact using APExBIO's high-purity nor-NOHA (acetate).

• FITC Goat Anti-Rabbit IgG (H+L) Antibody: Quantitative Fidel

  2026-06-25

  Discover how the FITC Goat Anti-Rabbit IgG (H+L) Antibody enables precise, sensitive detection in immunofluorescence assays. This article explores advanced quantitative applications and protocol insights, bridging immunodetection with recent fibrosis research.

• Exemestane in Precision Endocrine Research: Beyond Inhibitio

  2026-06-25

  Explore how Exemestane, a selective steroidal aromatase inhibitor, enables advanced precision in endocrine and breast cancer research. This article uniquely focuses on practical assay considerations and translational insights, offering a deeper scientific perspective.

• 5-Azacytidine: Mechanisms, Evidence & Protocols in Cancer Re

  2026-06-24

  5-Azacytidine (5-AzaC) is a cytosine analogue and potent DNA methyltransferase inhibitor used for DNA demethylation and gene reactivation. It demonstrates efficacy in suppressing metastasis via dormancy induction in cancer models, with benchmarked low micromolar IC50 values against leukemia and myeloma cells. This article details its mechanism, experimental benchmarks, and protocol parameters for advanced epigenetic research.

16346 records 1/1090 page Next 12345 下5页 Last page